These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 29856028)

  • 1. Assessing and Modulating Kynurenine Pathway Dynamics in Huntington's Disease: Focus on Kynurenine 3-Monooxygenase.
    Sathyasaikumar KV; Breda C; Schwarcz R; Giorgini F
    Methods Mol Biol; 2018; 1780():397-413. PubMed ID: 29856028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease.
    Beaumont V; Mrzljak L; Dijkman U; Freije R; Heins M; Rassoulpour A; Tombaugh G; Gelman S; Bradaia A; Steidl E; Gleyzes M; Heikkinen T; Lehtimäki K; Puoliväli J; Kontkanen O; Javier RM; Neagoe I; Deisemann H; Winkler D; Ebneth A; Khetarpal V; Toledo-Sherman L; Dominguez C; Park LC; Munoz-Sanjuan I
    Exp Neurol; 2016 Aug; 282():99-118. PubMed ID: 27163548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease.
    Thevandavakkam MA; Schwarcz R; Muchowski PJ; Giorgini F
    CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):791-800. PubMed ID: 20942784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease.
    Sathyasaikumar KV; Stachowski EK; Amori L; Guidetti P; Muchowski PJ; Schwarcz R
    J Neurochem; 2010 Jun; 113(6):1416-25. PubMed ID: 20236387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease.
    Campesan S; Green EW; Breda C; Sathyasaikumar KV; Muchowski PJ; Schwarcz R; Kyriacou CP; Giorgini F
    Curr Biol; 2011 Jun; 21(11):961-6. PubMed ID: 21636279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First molecular modeling report on novel arylpyrimidine kynurenine monooxygenase inhibitors through multi-QSAR analysis against Huntington's disease: A proposal to chemists!
    Amin SA; Adhikari N; Jha T; Gayen S
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5712-5718. PubMed ID: 27838184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis of kynurenine 3-monooxygenase inhibition.
    Amaral M; Levy C; Heyes DJ; Lafite P; Outeiro TF; Giorgini F; Leys D; Scrutton NS
    Nature; 2013 Apr; 496(7445):382-5. PubMed ID: 23575632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease.
    Toledo-Sherman LM; Prime ME; Mrzljak L; Beconi MG; Beresford A; Brookfield FA; Brown CJ; Cardaun I; Courtney SM; Dijkman U; Hamelin-Flegg E; Johnson PD; Kempf V; Lyons K; Matthews K; Mitchell WL; O'Connell C; Pena P; Powell K; Rassoulpour A; Reed L; Reindl W; Selvaratnam S; Friley WW; Weddell DA; Went NE; Wheelan P; Winkler C; Winkler D; Wityak J; Yarnold CJ; Yates D; Munoz-Sanjuan I; Dominguez C
    J Med Chem; 2015 Feb; 58(3):1159-83. PubMed ID: 25590515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-(6-phenylpyridazin-3-yl)benzenesulfonamides as highly potent, brain-permeable, and orally active kynurenine monooxygenase inhibitors.
    Kimura H; Suda H; Kassai M; Endo M; Deai Y; Yahata M; Miyajima M; Isobe Y
    Bioorg Med Chem Lett; 2021 Feb; 33():127753. PubMed ID: 33359168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A brain-permeable inhibitor of the neurodegenerative disease target kynurenine 3-monooxygenase prevents accumulation of neurotoxic metabolites.
    Zhang S; Sakuma M; Deora GS; Levy CW; Klausing A; Breda C; Read KD; Edlin CD; Ross BP; Wright Muelas M; Day PJ; O'Hagan S; Kell DB; Schwarcz R; Leys D; Heyes DJ; Giorgini F; Scrutton NS
    Commun Biol; 2019; 2():271. PubMed ID: 31372510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted deletion of kynurenine 3-monooxygenase in mice: a new tool for studying kynurenine pathway metabolism in periphery and brain.
    Giorgini F; Huang SY; Sathyasaikumar KV; Notarangelo FM; Thomas MA; Tararina M; Wu HQ; Schwarcz R; Muchowski PJ
    J Biol Chem; 2013 Dec; 288(51):36554-66. PubMed ID: 24189070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacophore-Based Virtual Screening of Novel Competitive Inhibitors of the Neurodegenerative Disease Target Kynurenine-3-Monooxygenase.
    Gotina L; Seo SH; Kim CW; Lim SM; Pae AN
    Molecules; 2021 May; 26(11):. PubMed ID: 34073016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The inhibition of the kynurenine pathway prevents behavioral disturbances and oxidative stress in the brain of adult rats subjected to an animal model of schizophrenia.
    Réus GZ; Becker IRT; Scaini G; Petronilho F; Oses JP; Kaddurah-Daouk R; Ceretta LB; Zugno AI; Dal-Pizzol F; Quevedo J; Barichello T
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Feb; 81():55-63. PubMed ID: 29030243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic alterations affecting the genes encoding the enzymes of the kynurenine pathway and their association with human diseases.
    Boros FA; Bohár Z; Vécsei L
    Mutat Res Rev Mutat Res; 2018; 776():32-45. PubMed ID: 29807576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The kynurenine pathway and neurodegenerative disease.
    Maddison DC; Giorgini F
    Semin Cell Dev Biol; 2015 Apr; 40():134-41. PubMed ID: 25773161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ablation of kynurenine 3-monooxygenase rescues plasma inflammatory cytokine levels in the R6/2 mouse model of Huntington's disease.
    Bondulich MK; Fan Y; Song Y; Giorgini F; Bates GP
    Sci Rep; 2021 Mar; 11(1):5484. PubMed ID: 33750843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway.
    Dounay AB; Tuttle JB; Verhoest PR
    J Med Chem; 2015 Nov; 58(22):8762-82. PubMed ID: 26207924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Kynurenine Pathway and Kynurenine 3-Monooxygenase Inhibitors.
    Hughes TD; Güner OF; Iradukunda EC; Phillips RS; Bowen JP
    Molecules; 2022 Jan; 27(1):. PubMed ID: 35011505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of N-(6-(5-fluoro-2-(piperidin-1-yl)phenyl)pyridazin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)methanesulfonamide as a brain-permeable and metabolically stable kynurenine monooxygenase inhibitor.
    Tsuboi K; Kimura H; Nakatsuji Y; Kassai M; Deai Y; Isobe Y
    Bioorg Med Chem Lett; 2021 Jul; 44():128115. PubMed ID: 34015507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kynurenine-3-monooxygenase: a review of structure, mechanism, and inhibitors.
    Smith JR; Jamie JF; Guillemin GJ
    Drug Discov Today; 2016 Feb; 21(2):315-24. PubMed ID: 26589832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.